Skin cancer ranges from highly treatable to life-threatening, depending on the type and how early it’s caught. The most common forms, basal cell carcinoma and squamous cell carcinoma, rarely kill but can cause serious tissue damage. Melanoma, while less common, is responsible for roughly 60,000 deaths worldwide each year. A rarer form called Merkel cell carcinoma is even more aggressive.
The Three Main Types and How They Compare
Not all skin cancers behave the same way. Basal cell carcinoma (BCC) is the most frequently diagnosed and the least dangerous. It grows slowly and almost never spreads to other parts of the body. But “not deadly” doesn’t mean harmless. BCC invades surrounding tissue, and when it develops on the face, ears, or near the eyes, delayed treatment can lead to ulceration, disfigurement, and permanent loss of function. It’s the kind of cancer that won’t kill you but can leave lasting physical damage if ignored.
Squamous cell carcinoma (SCC) sits in the middle. It’s also common and usually curable when caught early, but it has more potential to spread. Studies show metastasis rates of 3 to 9 percent, typically occurring one to two years after initial diagnosis. Certain factors raise that risk: tumors on the ears or lips, larger tumors, and cancers in people with weakened immune systems.
Melanoma is the type most people fear, and for good reason. It’s highly invasive and prone to spreading to lymph nodes and distant organs. Globally, about 331,000 people are diagnosed with melanoma each year. The good news is that survival depends enormously on timing. When melanoma is caught while still localized to the skin, the five-year survival rate is above 99 percent, according to American Cancer Society data. Once it spreads to nearby lymph nodes, that drops to 76 percent. If it reaches distant organs like the lungs, liver, or brain, the five-year survival rate falls to 35 percent.
Merkel Cell Carcinoma: Rare but Aggressive
Most people have never heard of Merkel cell carcinoma, but it’s worth knowing about. It’s a rare skin cancer, diagnosed at a rate of about 0.7 cases per 100,000 people per year in the U.S., yet its incidence has jumped 95 percent since 2000. Nearly one-third of patients already have cancer in their lymph nodes or distant sites at the time of diagnosis. Five-year survival rates reflect how aggressive it is: 51 percent for localized disease, 35 percent with lymph node involvement, and just 14 percent when it has spread to distant organs. That makes it comparable to or worse than melanoma in many scenarios.
What “Bad” Looks Like Beyond Survival
Even when skin cancer doesn’t threaten your life, treatment itself carries real consequences. The most common surgical approach for skin cancers on the face is a technique that removes tissue layer by layer, checking under a microscope until clear margins are achieved. It’s highly effective, but it can leave scars that take 12 to 18 months to fully mature and fade. Risks include infection, delayed wound healing, and in some cases, temporary or permanent loss of nerve function, meaning numbness or inability to move certain muscles near the surgical site.
For cancers near the eyes, nose, or ears, even a small tumor can require removal of tissue that’s difficult to reconstruct. This is why basal cell carcinoma, despite being called “the good kind” of skin cancer, still carries meaningful quality-of-life costs. The financial burden adds up, too. Annual healthcare spending on skin cancer treatment in the U.S. reached $8.9 billion between 2016 and 2018, with average per-person treatment costs of around $1,243 per year for non-melanoma types and $2,430 for melanoma.
Why Early Detection Changes Everything
The single biggest factor separating a minor procedure from a life-threatening diagnosis is how early the cancer is found. For melanoma, the gap between localized and distant-stage survival is the difference between a greater than 99 percent chance of being alive in five years and a 35 percent chance. That’s not a small margin.
The standard screening method you can do yourself is the ABCDE rule for evaluating moles and spots on your skin:
- Asymmetry: one half of the mole doesn’t match the other
- Border: edges are ragged, notched, or blurred rather than smooth
- Color: uneven shading with mixtures of brown, black, tan, white, red, or blue
- Diameter: larger than about 6 millimeters (roughly the size of a pencil eraser), though melanomas can be smaller
- Evolving: the spot has changed in size, shape, or color over recent weeks or months
No single feature is definitive on its own, but any of these changes warrants a closer look from a dermatologist. Catching melanoma before it penetrates deeper layers of skin is what keeps it in the “very treatable” category rather than the “very dangerous” one.
The Bottom Line on Severity
Skin cancer spans a wide spectrum. At one end, a small basal cell carcinoma on your arm might require a straightforward procedure and leave a barely visible scar. At the other end, a melanoma that has spread to your organs or a Merkel cell carcinoma diagnosed at a late stage can be fatal. Globally, non-melanoma skin cancers actually kill more people in total than melanoma does, roughly 69,000 deaths per year compared to about 59,000, simply because they’re so much more common. The critical variable in nearly every case is time. Skin cancer caught early is one of the most treatable cancers in medicine. Left alone, even the “mild” types can cause permanent harm, and the aggressive types can be deadly within a few years.